Nothing Special   »   [go: up one dir, main page]

ME01664B - Stabilizovani antihistaminski sirupi - Google Patents

Stabilizovani antihistaminski sirupi

Info

Publication number
ME01664B
ME01664B MEP-1999-235A MEP1999235A ME01664B ME 01664 B ME01664 B ME 01664B ME P1999235 A MEP1999235 A ME P1999235A ME 01664 B ME01664 B ME 01664B
Authority
ME
Montenegro
Prior art keywords
stabilizer
stabilized
aminopolycarboxylic acid
syrup containing
antihistamine syrup
Prior art date
Application number
MEP-1999-235A
Other languages
English (en)
Inventor
Rejean Fortin
Frank Guazzo
Elliot I Stupak
Imtiaz A Chaudry
Joel A Sequeira
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22209512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME01664(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ME01664B publication Critical patent/ME01664B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-1999-235A 1998-06-01 1999-05-27 Stabilizovani antihistaminski sirupi ME01664B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/088,128 US6132758A (en) 1998-06-01 1998-06-01 Stabilized antihistamine syrup
PCT/US1999/010469 WO1999062516A1 (en) 1998-06-01 1999-05-27 A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer

Publications (1)

Publication Number Publication Date
ME01664B true ME01664B (me) 2007-06-04

Family

ID=22209512

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-1999-235A ME01664B (me) 1998-06-01 1999-05-27 Stabilizovani antihistaminski sirupi

Country Status (29)

Country Link
US (4) US6132758A (me)
EP (1) EP1082117B1 (me)
JP (2) JP4166948B2 (me)
AR (1) AR019147A1 (me)
AT (1) ATE257705T1 (me)
AU (1) AU754469B2 (me)
CA (1) CA2333528C (me)
CO (1) CO5011119A1 (me)
CR (1) CR6035A (me)
DE (1) DE69914192T2 (me)
DK (1) DK1082117T3 (me)
EG (1) EG23908A (me)
ES (1) ES2211192T3 (me)
GC (1) GC0000330A (me)
GT (2) GT199900072AA (me)
HN (1) HN1999000081A (me)
JO (1) JO2099B1 (me)
ME (1) ME01664B (me)
MY (1) MY123325A (me)
NL (1) NL1012191C2 (me)
NO (1) NO329124B1 (me)
NZ (1) NZ508037A (me)
PA (1) PA8474201A1 (me)
PE (1) PE20000565A1 (me)
PT (1) PT1082117E (me)
RS (1) RS49609B (me)
SV (1) SV1999000068A (me)
TW (1) TW589197B (me)
WO (1) WO1999062516A1 (me)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
AU2277101A (en) * 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
AU2276801A (en) * 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
EP1239859A2 (en) * 1999-12-21 2002-09-18 Schering Corporation Use of desloratadine for treating allergic and inflammatory conditions in pediatric patients
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
AU4248400A (en) * 2000-04-14 2001-10-30 J Med Pharmaceuticals Inc Single-dose antihistamine/decongestant formulations for treating rhinitis
US20030216423A1 (en) * 2000-05-24 2003-11-20 Sergio Ulloa Stable liquid and solid formulations
PE20020055A1 (es) * 2000-05-25 2002-02-12 Schering Corp Formulaciones estables liquidas y solidas que comprenden una antihistamina no sedante y un descongestionante nasal
US20020035107A1 (en) * 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
IN192160B (me) * 2000-07-17 2004-02-28 Ranbaxy Lab
CN1446316A (zh) * 2000-08-02 2003-10-01 玛洛普有限公司 基于下丘脑－垂体－肾上腺轴异常的非溃疡性消化不良的诊断和处置
US6720002B2 (en) 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
PE20030545A1 (es) * 2001-10-31 2003-06-19 Schering Corp Formulaciones de jarabe de ribavirina
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US20040101563A1 (en) * 2002-07-18 2004-05-27 Kundu Subhas C. Storage stable antihistaminic syrup formulations
US20100092562A1 (en) * 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
US6635654B1 (en) 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
WO2004108700A1 (en) * 2003-03-12 2004-12-16 Teva Gyogyszergyar Reszvenytarsasag Processes for preparation of polymorphic forms of desloratadine
JP3881640B2 (ja) * 2003-08-08 2007-02-14 塩野義製薬株式会社 ロラタジンを含むドライシロップ剤
US20050069590A1 (en) 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US7758877B2 (en) * 2004-02-05 2010-07-20 Taro Pharmaceuticals U.S.A., Inc. Stable loratadine spill resistant formulation
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
GB0417909D0 (en) * 2004-08-11 2004-09-15 Novartis Consumer Health Sa Drop preparations
US20060093631A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20070009558A1 (en) * 2004-12-22 2007-01-11 David Harris Sugar-free storage-stable antihistaminic syrups
MX2007007613A (es) * 2004-12-22 2007-08-03 Schering Corp Formulaciones farmaceuticas.
US20060205752A1 (en) * 2005-03-14 2006-09-14 Keith Whitehead Stabilized hydrocodone pharmaceutical compositions with ethylenediaminetetraacetic acid
US20060275516A1 (en) * 2005-06-02 2006-12-07 Ram A N S Compositions and methods for the treatment of allergic rhinitis
PL1896022T3 (pl) * 2005-06-17 2013-03-29 Aft Pharmaceuticals Ltd Nowa kompozycja farmaceutyczna i jej zastosowanie w sposobie leczenia pacjentów z przekrwieniem śluzówki górnych dróg oddechowych
DOP2006000274A (es) 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
WO2007143382A2 (en) * 2006-06-07 2007-12-13 Morton Grove Pharmaceuticals, Inc. Oral liquid loratadine formulations and methods
JP2009542665A (ja) * 2006-06-29 2009-12-03 シェーリング コーポレイション 糖を含まない保存に安定な抗ヒスタミンシロップ
US20080014275A1 (en) * 2006-07-13 2008-01-17 Buehler Gail K Pharmaceutical suspensions and related methods
WO2008105920A1 (en) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Antihistamine combination
PL2002733T3 (pl) * 2007-06-08 2017-06-30 The Procter And Gamble Company Kompozycja zawierająca miód naturalny i sposoby jej sporządzania
US20090082385A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched desloratidine
CA2690490C (en) 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
JP5752578B2 (ja) * 2011-12-09 2015-07-22 ジェイ−メド ファーマシューティカルズ，インコーポレーティッド 鼻炎治療のための単一投与抗ヒスタミン薬／鬱血除去薬製剤
BR102012030828A2 (pt) 2012-12-03 2014-09-16 Ems Sa Composição farmacêutica compreendendo desloratadina e prednisolona e seu uso
CN104784110A (zh) * 2015-03-13 2015-07-22 浙江凯润制药有限公司 一种地氯雷他定糖浆制剂及其制备方法
US10576041B2 (en) 2016-09-26 2020-03-03 The Procter & Gamble Company Extended relief dosage form
CN109498569A (zh) * 2018-12-21 2019-03-22 湖北康源药业有限公司 一种氯雷他定糖浆及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570306B2 (en) * 1984-02-15 1988-03-10 Schering Corporation 8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5h-benzo (5,6) cyclohepta (1,2-b) pyridine and its salts.
US4783465A (en) * 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
US4829064A (en) * 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4975426A (en) * 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
NZ256346A (en) * 1992-10-09 1997-04-24 Procter & Gamble Medicaments containing 3-l-menthoxypropane-1,2-diol for treating cold symptoms
FI941777A (fi) * 1993-04-16 1994-10-17 Mcneil Ppc Inc Vesipitoinen farmaseuttinen suspensio ja menetelmä sen valmistamiseksi
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
JPH09124484A (ja) * 1995-10-27 1997-05-13 Schering Purau Kk 点眼剤
US5912007A (en) * 1996-02-29 1999-06-15 Warner-Lambert Company Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same
BR9712705A (pt) * 1996-10-31 1999-10-26 Schering Corp Composição para o tratamento da asma, contendo loratadina e um descongestionante
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup

Also Published As

Publication number Publication date
PE20000565A1 (es) 2000-07-05
CR6035A (es) 2008-11-26
NL1012191C2 (nl) 2000-01-04
EP1082117A1 (en) 2001-03-14
NZ508037A (en) 2002-11-26
US20050261280A1 (en) 2005-11-24
GT199900072AA (es) 2000-11-16
EG23908A (en) 2007-12-30
GT199900072A (es) 2000-11-16
NL1012191A1 (nl) 1999-12-03
TW589197B (en) 2004-06-01
US6132758A (en) 2000-10-17
AU4308599A (en) 1999-12-20
JP2005015485A (ja) 2005-01-20
DE69914192T2 (de) 2004-10-21
NO329124B1 (no) 2010-08-30
US20030152595A1 (en) 2003-08-14
CA2333528A1 (en) 1999-12-09
MY123325A (en) 2006-05-31
AR019147A1 (es) 2001-12-26
NO20006079D0 (no) 2000-11-30
SV1999000068A (es) 2000-06-23
RS49609B (sr) 2007-06-04
HN1999000081A (es) 1999-08-23
ES2211192T3 (es) 2004-07-01
PT1082117E (pt) 2004-05-31
CO5011119A1 (es) 2001-02-28
DK1082117T3 (da) 2004-05-03
EP1082117B1 (en) 2004-01-14
NO20006079L (no) 2000-11-30
GC0000330A (en) 2007-03-31
AU754469B2 (en) 2002-11-14
YU23599A (sh) 2001-07-10
US20020132805A1 (en) 2002-09-19
US6939550B2 (en) 2005-09-06
PA8474201A1 (es) 2001-07-31
DE69914192D1 (de) 2004-02-19
JP4166948B2 (ja) 2008-10-15
JO2099B1 (en) 2000-05-21
US6514520B2 (en) 2003-02-04
WO1999062516A1 (en) 1999-12-09
ATE257705T1 (de) 2004-01-15
JP2002516860A (ja) 2002-06-11
CA2333528C (en) 2002-07-02

Similar Documents

Publication Publication Date Title
ME01664B (me) Stabilizovani antihistaminski sirupi
AP9901505A0 (en) (4-arylsulfonylamino)- etrah dropyran-4-carboxylic acid hydroxamides
SG93823A1 (en) Aryl-acrylic acid esters
IL139470A0 (en) Oxyiminoalkanoic acid derivatives
GB2339040C (en) Executing partial-width packed data instructions
EG24140A (en) New 3-aryl-2-hydroxypropionic acid derivative
HK1035525A1 (en) Aminomethylcarboxylic acid derivatives
HUP0003881A3 (en) Amidocarboxylic acid derivatives
GB0023549D0 (en) Executing partial-width packed data instructions
AP9901457A0 (en) Novel dihydroxyexanoic acid derivatives
ZA988062B (en) 4-hydroxyquinoline-3-carboxylic acid derivatives as light stabilizers
PL360388A1 (en) Aza-amino acid derivatives (factor xa-inhibitors 15)
TW414420U (en) Ribbon cable insertion slot
FI942725A0 (fi) Haaraketjuista alfaketohappodenydrogenaasikompleksia koodaavia geenejä Streptomyces avermitiliksesta
IL135639A0 (en) Novel methylenebisphosphonic acid derivatives
GB0017712D0 (en) A driver primarily for posts
AU3962700A (en) Nucleic acid molecule comprising a nucleic acid sequence coding for a hemocyanin
AU2434099A (en) Bleach stabiliser including fatty acid salts
SI1070058T1 (en) (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
GB9924911D0 (en) Novel phosphonocarboxylic acid esters
TW363639U (en) Improved structure for warehouse board
PL108551U1 (en) Hold-down bar of a pillar-and-transom structure
GB9822490D0 (en) Nucleic acid
GB9823481D0 (en) Nucleic acid
TW349434U (en) Structure improvement for Yo-Yo